Abstract
Background
Cough is the most common respiratory symptom in children with mild coronavirus disease 2019 (COVID-19); however, evidence regarding the duration and severity of COVID-19-related cough is sparse. Herein, we investigated the correlation between cough severity/duration and disease duration in children with allergic diseases following COVID-19.
Methods
This single-center, retrospective case-control study was conducted at the Department of Pediatrics, Peking University Third Hospital, from February 6–13, 2023. Children aged 0–16 completed a questionnaire survey collecting basic information and weekly cough scores for 8 consecutive weeks after COVID-19 in December 2022. The Kaplan–Meier method was used to draw event curves, and the log-rank method was used to compare inter-group differences. Stepwise regression was applied for multivariate analysis of correlations between age, sex, allergic diseases, and the degree and duration of cough following COVID-19.
Results
Overall, 686 children were included, of whom 183 (26.7%) had allergic diseases and 503 (73.3%) did not. Kaplan–Meier analysis identified significant differences between patients with and without allergic disease (log-rank test, P = 0.002) and between patients with no allergic disease and those with one and more than one allergic disease (log-rank test, P = 0.003). Multivariate regression identified a link between the presence of more than one allergic disease and coughing for >4 weeks after infection (P < 0.001). Allergic disease was the primary factor linked to cough symptoms lasting 8 weeks and cough severity (P < 0.001).
Conclusions
Allergic disease contributes to the prolonged duration and severity of coughing in children with mild COVID-19.
Keywords: COVID-19, cough, allergic disease, respiratory infection, children
1. Introduction
Since December 2022, Beijing has experienced a rapidly spreading local outbreak of the novel coronavirus disease 2019 (COVID-19). According to the results of genome sequencing analysis, >90% of local infections in Beijing are caused by the omicron variants BA.5.2 and BF.7 (1). According to a preliminary analysis by the Beijing Center for Disease Prevention and Control, 80% of Beijing's permanent residents experienced infection. Although most patients recover quickly, a small number develop persistent symptoms following COVID-19, of which cough is one of the most common symptoms. Patients with allergic diseases such as asthma, allergic rhinitis, and specific dermatitis are more susceptible to airway hyperresponsiveness due to type 2 inflammation. The anaphylactic process by which allergy occurs involves the activation and maturation of dendritic cells in response to exposure to allergens, epithelial alarms, and infectious agents, followed by the clonal expansion of allergen-specific Th2 cells, which are polarized and tend to produce type 2 cytokines (2). However, whether the duration and severity of cough in such patients after COVID-19 are affected by type 2 inflammation and viral infection remains unclear.
In contrast to the manifestations of adult coronavirus, severe infection is rare in children, and mild or asymptomatic infections are more common. In a single-center retrospective study of 171 children with COVID-19, 4% had a cough that did not disappear 3–6 months after infection (3). Another prospective study showed that children with asthma are more likely to develop persistent cough symptoms following COVID-19 (4). At present, most studies on the period after COVID-19 have many limitations, including small sample sizes, lack of a control group, lack of a standardized description of symptoms, lack of detailed stratified analysis, and limited data on children as research participants (5).
To address this knowledge gap, the present study investigated whether allergic diseases could affect the duration and coughing score in children with COVID-19.
2. Materials and methods
2.1. Study design and participants
This case-control study was designed to explore the cough symptoms, severity, and influencing factors of children with allergic diseases following COVID-19 to allow for optimized targeted treatment and follow-up.
Children aged 0–16 with mild COVID-19 since December 2022 who visited the Department of Pediatrics, Peking University Third Hospital, from February 6–13, 2023, were included in the study. COVID-19 was defined as follows: Clinical manifestations of COVID-19, including dry throat, sore throat, cough, and fever; and presence of one or more of the following etiological and serological test results: (1) Positive COVID-19 nucleic acid test, (2) positive COVID-19 antigen test, (3) positive COVID-19 isolation and culture, and (4) Novel coronavirus specific immunoglobulin G antibody levels four times higher in the convalescent phase than in the acute phase (1). Mild symptoms were defined as the main manifestations of respiratory tract infections, such as dry throat, sore throat, cough, and fever (1).
This study examined the influence of allergic factors on cough in children with COVID-19. The case group comprised children with previous allergic diseases, and the control group comprised children without allergic diseases.
The sample size was calculated using PASS software, using two-sample t-tests assuming equal variance and setting the target power to 0.9; we calculated that the study needed to meet the sample size of 46, and the sample size of the case group and the control group were 23 each.
2.2. Influencing factors under investigation
The following influencing factors were investigated in the present analysis:
-
(1)
Basic characteristics including sex and age.
-
(2)
Presence of basic diseases: According to the different characteristics of combined allergies, patients were divided into those without allergic diseases and those with allergic diseases (allergic rhinitis, eczema, asthma, allergic conjunctivitis, food allergies, drug allergies). Based on the number of combined allergic diseases, the patients were divided into no allergic disease, one allergic disease, and more than two allergic diseases.
-
(3)
Symptoms of acute COVID-19 including fever, cough, sore throat, dyspnea, abdominal pain, diarrhea, and muscle aches.
-
(4)
Score of cough symptoms over 8 consecutive weeks after COVID-19. Cough scores were assigned to each patient once a week for 8 consecutive weeks after infection to assess the level of cough, as follows: 0, no cough; 1, occasional cough (excluding cough after exercise); 2, frequent cough mildly affecting life or sleep, or cough after exercise; 3, frequent cough seriously affecting life or sleep. According to the cough score, the severity of the cough was graded as follows: 0 and 1 points were mild, and 2 and 3 points were severe.
2.3. Data source
A questionnaire survey was conducted, and written informed consent for participation was obtained before the study. This study was approved by the Ethics Committee of the Peking University Third Hospital (approval number: 2023 No. 007-02).
The questionnaire was designed collaboratively between pediatricians, epidemiologists, and medical ethicists. Parents scanned the QR code on their mobile phones, applied the questionnaire star applet, and filled in the requested information. The questionnaire collected data regarding the following characteristics: 1. Basic characteristics, including sex, age, weight, and height; 2. Underlying diseases (whether patients had comorbid allergic diseases); 3. Symptoms of acute COVID-19, including fever, cough, sore throat, dyspnea, abdominal pain, diarrhea, and muscle aches; 4. Weekly cough score after COVID-19 for 8 consecutive weeks. All information was completed before submission, and the quality control officer conducted quality control of the collected information.
SPSS 23.0 software was used to verify the validity and reliability of the questionnaire. Cronbach's α and the Kaiser–Meyer–Olkin (KMO) test were employed.
2.4. Bias
This study did not investigate infectious factors other than COVID-19 (such as Mycoplasma pneumoniae and adenovirus infection) or allergen results. The COVID-19 outbreak in Beijing in December 2022 was a centralized outbreak with a short duration and a centralized research information collection time. As such, environmental factors, infection, and allergen exposure did not affect the results during the observation period.
This study did not include an analysis of medication factors, and the combination of medications was complex. Many drug combinations are associated with underlying diseases in children. Children with allergic diseases, the use of anti-allergic drugs, and the simultaneous inclusion of allergic disease and medication factors may cause the same influencing factors to be analyzed repeatedly.
In the study design, the cough assessment time was measured in weeks, which may have affected the accuracy of the confidence interval in the survival curve analysis. However, using 1 week as the unit is conducive to reviewing children and parents and can more accurately reflect the degree of coughing.
2.5. Statistical analysis
R3.5.3 statistical software (R Foundation 3.5.3, Vienna, Austria) was used for data analysis. Counting data are described by case number and/or percentage, inter-group comparisons are described by X2 statistics, measurement data are shown as the mean ± standard deviation and inter-group comparisons are described by the U test. The t-test was performed to analyze continuous variables, and the X2 test was used to analyze categorical variables. The Kaplan–Meier method was performed to draw event curves, and the log-rank method was used to compare the differences in event curves between groups. Cox regression with stepwise selection was used in the multifactor analysis. A P-value of <0.05 indicated statistical significance.
3. Results
3.1. The validity and reliability of the questionnaires
The results showed that the effective questionnaire was 823, the Alpha coefficient was 0.693, and the KMO was 0.802, indicating that the reliability of the questionnaire was acceptable and the validity was appropriate.
3.2. Characteristics of the study participants
During the study period, 823 children provided informed consent for participation, excluding one case of severe illness and 136 children without novel coronavirus pneumonia. A total of 686 children were included in the study, of whom 183 (26.7%) had allergic diseases and 503 (72.3%) had no allergic diseases. Both the case group and the control group met the sample size requirements. The workflow of the research analysis is shown in Figure 1.
Figure 1.
Analysis workflow.
Between February 6 and 13, 2023, 686 children aged 0–16 with mild COVID-19 in December 2022 were enrolled in the pediatric outpatient clinic of Peking University Third Hospital. Basic data of the study participants are shown in Table 1; 388 (56.6%) were boys, and 298 (43.4%) were girls. A total of 183 patients (26.7%) had allergic diseases, while the remaining 503 patients (72.3%) had no allergic disease. Allergic diseases were associated with allergic rhinitis (73.56%), atopic dermatitis (36.54%), asthma (23.56%), allergic conjunctivitis (15.38%), food allergies (37.98%), drug allergies (2.88%), and other allergic diseases (7.21%). Table 2 shows the grouping according to the duration of the cough and influencing factors after COVID-19. Among the children with a cough lasting for more than 4 weeks following COVID-19, 43 (42.2%) were girls, with a median age of 6.75 (0.00–15.9). Allergic diseases were present in 41 cases (40.2%), of which 32 (31.4%) suffered from allergic rhinitis, 12 (11.8%) from asthma, 8 (7.8%) from allergic conjunctivitis, and 20 (19.6%) had atopic dermatitis, 15 (14.7%) had food allergies, 1 (1.0%) had drug allergies, and 3 (2.9%) suffered from other allergic diseases.
Table 1.
Characteristics of the study participants.
| Characteristic | Children (n = 686) |
|---|---|
| Sex | Male 388 (56.6%), Female 298 (43.4%) |
| Age (median, years) | 6.35 (0.01–16) |
| Presence of allergic diseases | 183 (26.7%) |
| Manifestations of COVID-19 | |
| Fever | 643 (93.7%) |
| Cough | 425 (61.95%) |
| Runny nose | 175 (25.52%) |
| Tachypnea | 14 (2.07%) |
| Chest tightness or shortness of breath | 16 (2.31%) |
| Decreased exercise tolerance | 58 (8.51%) |
COVID-19, coronavirus disease 2019.
Table 2.
Grouping and influencing factors of cough duration following COVID-19.
| Cough course >4 weeks | Cough course ≤4 weeks | |
|---|---|---|
| Sex | Female 43 (42.2%) | Female 255 (43.7%) |
| Age (median, years) | 6.75 (0.00–15.9) | 6.25 (0.00–17.8) |
| Presence of allergic diseases | 41 (40.2%) | 142 (24.3%) |
| Allergic pathologies | ||
| Allergic rhinitis | 32 (31.4%) | 102 (17.5%) |
| Asthma | 12 (11.8%) | 36 (6.2%) |
| Allergic conjunctivitis | 8 (7.8%) | 19 (3.3%) |
| Atopic dermatitis | 20 (19.6%) | 47 (8.0%) |
| Food allergies | 15 (14.7%) | 55 (9.4%) |
| Drug allergies | 1 (1.0%) | 4 (0.7%) |
| Other allergic diseases | 3 (2.9%) | 5 (0.9%) |
COVID-19, coronavirus disease 2019.
3.3. Kaplan–Meier event curves
Overall, in the 8 consecutive weeks after COVID-19, cough generally showed a downward trend (Figure 2A). The Kaplan–Meier curves did not differ between sexes (Figure 2B). However, differences were found when patients were stratified by the presence and number of allergic diseases (log-rank test, P = 0.002 and 0.003, respectively), as shown in Figures 2C, 2D. Kaplan–Meier event analysis showed that the overall non-event rate was 10.45%, β = 2 (95% confidence interval, 1.81–2.93), while the mean time to event was 2.82 weeks, with a standard error of 0.09.
Figure 2.
Kaplan–Meier event analyses for cough following COVID-19. (A) Cough following COVID-19. (B) Cough after COVID-19 across sexes. (C) Cough after COVID-19 across groups with and without allergic diseases. (D) Cough after COVID-19 in groups stratifies by number of allergic diseases.
3.4. Cox regression
T-tests were used to analyze continuous variables, and the chi-squared test was used to analyze categorical variables. The U-test was used to analyze age as this data did not conform to normality. Age [hazard ratio = 0.98 (0.96, 1.00), P = 0.037], presence of allergic diseases [hazard ratio = 0.79 (0.66, 0.96), P = 0.015], and number of allergic diseases [hazard ratio = 0.73 (0.58, 0.92), P = 0.008] were all closely correlated with symptom prognosis in the 8 weeks following COVID-19 (P < 0.05), as shown in Table 3. However, sex [hazard ratio = 0.97 (0.83,1.14), P = 0.75] was not correlated with symptom prognosis in the 8 weeks following COVID-19.
Table 3.
Correlation between factors and multifactor analysis results for cough presence following COVID-19 .
| Characteristic | Cough did not disappear (n = 74) |
Cough disappeared (n = 612) |
Statistics | P | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|---|---|
| Hazard Ratio | P | Hazard Ratio | P | |||||
| (95% CI) | (95% CI) | |||||||
| Age (year) | 0.98 [0.96, 1.00] | 0.037 | 0.98 [0.96, 1.00] | 0.056 | ||||
| Mean (SD) | 7.53 (4.47) | 6.37 (4.22) | U = 25,888.500 | 0.0439 | ||||
| Median [min, max] | 7.60 [0.200, 15.9] | 6.30 [0.00, 17.8] | ||||||
| Sex | 0.97 [0.83, 1.14] | 0.75 | ||||||
| Female | 26 (35.1%) | 272 (44.4%) | X2 = 2.329 | 0.127 | ||||
| Male | 48 (64.9%) | 340 (55.6%) | ||||||
| Allergic disease | 0.79 [0.66, 0.96] | 0.015 | 0.80 [0.67, 0.97] | 0.021 | ||||
| None | 41 (55.4%) | 462 (75.5%) | X2 = 13.615 | <0.001 | ||||
| Present | 33 (44.6%) | 150 (24.5%) | ||||||
| Number of allergic diseases | ||||||||
| 0 | 41 (55.4%) | 463 (75.7%) | X2 = 16.115 | <0.001 | ||||
| 1 | 10 (13.5%) | 62 (10.1%) | 0.91 [0.70, 1.18] | 0.468 | ||||
| ≥2 | 23 (31.1%) | 87 (14.2%) | 0.73 [0.58, 0.92] | 0.008 | ||||
COVID-19, coronavirus disease 2019; CI, confidence interval; SD, standard deviation.
Multifactor analysis showed that the presence of allergic diseases was an independent prognostic factor affecting cough in children 8 weeks after COVID-19 (hazard ratio = 0.80, P = 0.021), as shown in Table 3. However, age did not affect cough in children 8 weeks after COVID-19 [0.98 (0.96,1.00), P = 0.056].
3.5. Analysis of risk factors for developing a chronic cough
We analyzed age, sex, the presence and number of allergic diseases, and allergic pathologies as influencing factors. The results of the univariate analysis showed that a history of allergic diseases [hazard ratio = 0.81 (0.67,0.98), P = 0.027], the presence of ≥2 allergic diseases [hazard ratio = 0.73 (0.58,0.93), P = 0.011], allergic rhinitis [hazard ratio = 0.79 (0.64,0.98), P = 0.03], and atopic dermatitis [hazard ratio = 0.70 (0.52,0.95), P = 0.021], on the duration of cough >4 weeks had significant differences (all P < 0.05, Table 4).
Table 4.
Cough duration > 4 weeks of overall risk factor analysis results.
| Characteristic | Cough course ≤4 weeks (n = 584) | Cough course >4 weeks (n = 102) | P-value |
|---|---|---|---|
| Age (y) | |||
| Mean (SD) | 6.40 (4.24) | 7.05 (4.33) | 0.185 |
| Median [min, max] | 6.25 [0.00, 17.8] | 6.75 [0.00, 15.9] | |
| Sex | |||
| Female | 255 (43.7%) | 43 (42.2%) | 0.777 |
| Male | 329 (56.3%) | 59 (57.8%) | |
| Allergic disease | |||
| None | 442 (75.7%) | 61 (59.8%) | <0.001 |
| Present | 142 (24.3%) | 41 (40.2%) | |
| Number of allergic diseases | |||
| 0 | 443 (75.9%) | 61 (59.8%) | <0.001 |
| 1 | 60 (10.3%) | 12 (11.8%) | |
| ≥2 | 81 (13.9%) | 29 (28.4%) | |
| Allergic pathologies | |||
| Allergic rhinitis | 32 (31.4%) | 102 (17.5%) | 0.03 |
| Asthma | 12 (11.8%) | 36 (6.2%) | 0.376 |
| Allergic conjunctivitis | 8 (7.8%) | 19 (3.3%) | 0.068 |
| Atopic dermatitis | 20 (19.6%) | 47 (8.0%) | 0.021 |
| Food allergies | 15 (14.7%) | 55 (9.4%) | 0.19 |
| Drug allergies | 1 (1.0%) | 4 (0.7%) | 0.896 |
| Other allergic diseases | 3 (2.9%) | 5 (0.9%) | 0.181 |
SD, standard deviation.
The results of the multivariate analysis showed that the presence of ≥2 allergic diseases was an independent predictor of coughs lasting >4 weeks after COVID-19 [β = 0.956, 95% confidence interval (1.575, 4.293), P < 0.001]. The allergic pathologies had no effect on coughs lasting more than >4 weeks.
3.6. Analysis of risk factors for severe cough lasting for 8 weeks after COVID-19
Analysis of risk factors for developing chronic cough revealed a statistically significant effect between the presence/number of allergic diseases with chronic cough lasting for 8 weeks, and persistent cough severity (all P < 0.05, Table 5). However, neither age or sex had a significant effect on coughs lasting for 8 weeks.
Table 5.
Overall risk factor analysis for risk factors potentially influencing severe cough lasting for 8 weeks following COVID-19.
| Characteristic | Mild | Severe | P |
|---|---|---|---|
| (n = 668) | (n = 18) | ||
| Age (year) | |||
| Mean (SD) | 6.49 (4.27) | 6.84 (4.03) | 0.712 |
| Median [min, max] | 6.40 [0.00, 17.8] | 5.75 [0.900, 15.7] | |
| Sex | |||
| Female | 293 (43.9%) | 5 (27.8%) | 0.174 |
| Male | 375 (56.1%) | 13 (72.2%) | |
| Allergic disease | |||
| None | 495 (74.1%) | 8 (44.4%) | 0.0112 |
| Present | 173 (25.9%) | 10 (55.6%) | |
| Number of allergic diseases | |||
| 0 | 496 (74.3%) | 8 (44.4%) | 0.011 |
| 1 | 69 (10.3%) | 3 (16.7%) | |
| ≥2 | 103 (15.4%) | 7 (38.9%) | |
COVID-19, coronavirus disease 2019; SD, standard deviation.
The results of the multivariate analysis showed that the combination of allergic disease was an independent predictor of the duration of cough up to 8 weeks, as well as the severity of cough [β=1.27, 95% confidence interval (1.39, 9.21), P = 0.008].
4. Discussion
COVID-19 has greatly impacted global health, human health, and life, with children also affected by this novel disease. Although the overall clinical manifestations in children are generally mild, and prognoses are good (2), some children develop chronic symptoms after infection, among which respiratory symptoms and cough are the most common (6).
The National Institute for Health and Clinical Excellence guidelines define long COVID-19 as symptoms lasting >4–12 weeks after viral infection, not caused by subsequent infection with other diseases (7). In previous studies, cough was identified as one of the most common symptoms of COVID-19, and many children presented to the hospital within 12 weeks of infection, especially when the cough lasted >4 weeks and had developed into a chronic cough. These cases were often serious enough to attract the attention of pediatricians and require treatment. However, only a few studies have investigated the factors influencing cough in this cohort (8, 9).
In our study, we found that the course and severity of cough in children with mild COVID-19 correlated with the presence of comorbid allergic diseases. Several existing studies on COVID-19 have investigated whether allergy plays a protective role in the acute phase of infection (10–12); however, specific clinical studies on COVID-19 in children are insufficient. This study, therefore, provides valuable clinical evidence of the influencing factors in children with cough caused by COVID-19.
Viral infections, including COVID-19, are also closely associated with autoimmunity, as they can increase airway reactivity and trigger symptoms such as coughing. Allergic diseases in children are characterized by type 2 inflammation, which promotes airway inflammation. Previous studies have elucidated the mechanisms underlying the association between COVID-19 and allergic diseases, showing that COVID-19 causes respiratory symptoms by damaging the airway mucosa and inducing airway inflammation and hypersecretion of airway mucus (13). During infection, viral spikes are inserted into respiratory epithelial cells by binding to the ACE2 receptor, allowing entry into the cells and triggering infection in children. This process requires the promotion of cell entry through proteolytic cleavage involving the proteases transmembrane protease serine 2 (TMPRSS2) and cathepsin L (14, 15). TMPRSS2 reduces the recognition of viruses through human defense mechanisms (16); however, type 2 inflammation, in which interleukin (IL)-4, IL-5, and IL-3 are important inflammatory factors, acts as the inflammatory basis of allergic diseases in children (17). Studies have shown that IL-13 also acts on TMPRSS2, increasing airway mucus production and airway reactivity (14). The present study showed that allergic diseases affect the duration and severity of coughing in children with COVID-19. In children with allergic diseases, cough symptoms persist after infection, sometimes developing into a chronic cough. The results of this study are consistent with the role of inflammation in the aforementioned pathogenesis.
This study has some limitations. First, a sampling survey was conducted. Although information was continuously included during the study period, bias caused by sampling cannot be excluded, and the results may not be universally applicable beyond the study population. Further, the questionnaire was not validated in a larger pilot study. Second, the data relied on parental or self-reported symptoms, which may have introduced a risk of recall bias. However, COVID-19 received widespread attention during this transmission cycle. As a result, the participants were likely to be knowledgeable about symptoms during infection; therefore, recall bias was considered minimal. Third, drug use factors were not analyzed in this study. Drug combinations are complicated, and many drugs are related to underlying diseases in children. Children with allergic diseases use anti-allergy drugs; therefore, allergy and drug-use factors were included simultaneously, and the same influencing factors may be analyzed repeatedly. Fourth, this study did not include infectious factors other than COVID-19 (such as Mycoplasma pneumoniae and adenovirus infections) and did not investigate allergen results. Considering that the December 2022 COVID-19 pandemic wave in Beijing was a concentrated outbreak, the epidemic time was short, and the research information collection time was limited. During the study observation period, environmental factors, infection effects, and allergen exposure effects did not cause bias in the results of the observed participants. The results of another drug use analysis on this subject showed that the drug use of the target population during COVID-19 did not affect the cough score. Therefore, factors not included in drug use did not affect the results of this study.
In addition to type 2 inflammation, other inflammatory pathways between COVID-19 and allergic diseases warrant further exploration. Further, for children with COVID-19, the problems of airway remodeling and changes in airway structure after infection also deserve more attention, in addition to the association between viral infection and the immune system.
In conclusion, allergic diseases may be associated with the subsequent course and severity of coughing in children with COVID-19. However, these results need to be confirmed in future studies with larger sample sizes. Clinicians should consider that persistent coughing may be prolonged following COVID-19 in children with allergies. Children with severe cough should be differentiated from those with allergic diseases and administered symptomatic medication.
Acknowledgments
We would like to thank all the families who participated in this study. We would like to thank Editage (www.editage.cn) for English language editing. This work was supported by the Peking University Third Hospital.
Funding Statement
The author(s) declare financial support was received for the research, authorship, and/or publication of this article.
The Clinical Cohort Construction Program of Peking University Third Hospital funded this study [Grant no: BYSYDL2023001-14].
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by The Ethics Committee of the Peking University Third Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.
Author contributions
LLiu: Conceptualization, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing. LZh: Data curation, Formal Analysis, Visualization, Writing – original draft. PZ: Data curation, Methodology, Supervision, Validation, Writing – original draft. WZ: Data curation, Formal Analysis, Investigation, Methodology, Validation, Writing – original draft. LLi: Data curation, Investigation, Writing – original draft. LZe: Methodology, Writing – original draft. NL: Methodology, Writing – original draft. RZ: Methodology, Writing – original draft. TH: Project administration, Supervision, Writing – review & editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
- 1.China NHCO. Diagnosis and treatment plan for COVID-19 (trial version 10). China Med. (2023) 18:161–6. 10.1186/s13020-023-00868-9 [DOI] [Google Scholar]
- 2.van Neerven RJ, Knol EF, Ejrnaes A, Würtzen PA. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol. (2006) 141:119–29. 10.1159/000094714 [DOI] [PubMed] [Google Scholar]
- 3.Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child Adolesc Health. (2021) 5:e22–3. 10.1016/S2352-4642(21)00124-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Esmaeilzadeh H, Sanaei DA, Mortazavi N, Fatemian H, Vali M. Persistent cough and asthma-like symptoms post COVID-19 hospitalization in children. BMC Infect Dis. (2022) 22:244. 10.1186/s12879-022-07252-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Case SM, Son MB. COVID-19 in pediatrics. Rheum Dis Clin North Am. (2021) 47:797–811. 10.1016/j.rdc.2021.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bossley CJ, Kavaliunaite E, Harman K, Cook J, Ruiz G, Gupta A. Post-acute COVID-19 outcomes in children requiring hospitalisation. Sci Rep. (2022) 12:8208. 10.1038/s41598-022-12415-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19 (2018). Available online at: https://www.nice.org.uk/guidance/ng188 (accessed December 18, 2020).
- 8.Denina M, Pruccoli G, Scolfaro C, Mignone F, Zoppo M, Giraudo I, et al. Sequelae of COVID-19 in hospitalized children: a 4-months follow-up. Pediatr Infect Dis J. (2020) 39:e458–9. 10.1097/INF.0000000000002937 [DOI] [PubMed] [Google Scholar]
- 9.Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA. (2021) 326:869–71. 10.1001/jama.2021.11880 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Ren J, Pang W, Luo Y, Cheng D, Qiu K, Rao Y, et al. Impact of allergic rhinitis and asthma on COVID-19 infection, hospitalization, and mortality. J Allergy Clin Immunol Pract. (2022) 10:124–33. 10.1016/j.jaip.2021.10.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Reznikov LR, Norris MH, Vashisht R, Bluhm AP, Li D, Liao YJ, et al. Identification of antiviral antihistamines for COVID-19 repurposing. Biochem Biophys Res Commun. (2021) 538:173–9. 10.1016/j.bbrc.2020.11.095 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Fidan C, Aydogdu A. As a potential treatment of COVID-19: montelukast. Med Hypotheses. (2020) 142:109828. 10.1016/j.mehy.2020.109828 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. (2003) 426:450–4. 10.1038/nature02145 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. (2020) 181:281–92. 10.1016/j.cell.2020.02.058 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Schuler BA, Christian HA, Plosa EJ, Taylor CJ, Jetter C, Negretti NM, et al. Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 infection in the lung epithelium. J Clin Invest. (2020) 131:e140766. 10.1172/JCI140766 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. (2007) 13:139–45. 10.1038/nm1551 [DOI] [PubMed] [Google Scholar]
- 17.Chatziparasidis G, Kantar A. COVID-19 in children with asthma. Lung. (2021) 199:7–12. 10.1007/s00408-021-00419-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.